Authors:
Singer, J
Thorne, A
Khorasheh, S
Raboud, JM
Wu, AW
Salit, I
Tsoukas, CM
Lemieux, C
Shafran, SD
Citation: J. Singer et al., Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010), INT J STD A, 11(4), 2000, pp. 212-219
Authors:
Gordin, FM
Sullam, PM
Shafran, SD
Cohn, DL
Wynne, B
Paxton, L
Perry, K
Horsburgh, CR
Citation: Fm. Gordin et al., A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex, CLIN INF D, 28(5), 1999, pp. 1080-1085
Authors:
Singer, J
Thorne, A
Phillips, P
Rachlis, AR
Miller, M
Gill, MJ
Smaill, FM
Schlech, WF
Senay, H
Shafran, SD
Citation: J. Singer et al., Predictors of survival and eradication of Mycobacterium avium complex bacteremia (MAC) in AIDS patients in the Canadian Randomized MAC Treatment Trial, AIDS, 13(5), 1999, pp. 575-582
Authors:
Shafran, SD
Talbot, JA
Chomyc, S
Davison, E
Singer, J
Phillips, P
Salit, I
Walmsley, SL
Fong, IW
Gill, MJ
Rachlis, AR
Lalonde, RG
Citation: Sd. Shafran et al., Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin?, CLIN INF D, 27(6), 1998, pp. 1401-1405